entertainment -WSS

entertainment

author：leisure time 2025-09-03 12:10:24 - browse：4892

Alnylam headquarters — Kristoffer Tripplaar/Sipa USA/AP

Alnylam Pharmaceuticals said Thursday that sales of its treatments for rare diseases grew 43% in the second quarter compared to the year-ago period, as the biotech prepares for a key meeting with the Food and Drug Administration in September.

Net product sales in the quarter were $306 million, led by Amvuttra, the company’s RNAi treatment for hereditary ATTR, with sales of $132 million, exceeding Wall Street forecasts. Sales of Onpattro, its older medicine for hereditary ATTR, were $91 million, slightly less than expectations.

The FDA has scheduled a meeting of outside experts on Sept. 13 to discuss the company’s application to expand the indication for Onpattro to include ATTR-CM, a related condition that affects the heart. The FDA decision is due by Oct. 8. An expansion would open a much larger market for the drug than its current approval, which largely targets nerve-related damage.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Novavax promises a turnaround & Lilly roils the obesity market
Next article： UnitedHealth has 90,000 doctors — 10% of all physicians in U.S.

explore

WSS

UnitedHealth has 90,000 doctors — 10% of all physicians in U.S.

The EPA's new lead rule: How one expert crunched the numbers

BIO selects John Crowley as new CEO

Medicare solvency divides Republicans at the presidential debate

Will the market for weight loss drugs really reach $100 billion?

White House calls on federal agencies to crack down on AI abuses

Wikipedia

entertainment

hotspot

At least 13 dead in Texas as scorching temps continue

What to do when lifesaving products contribute to climate change

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

White House calls on federal agencies to crack down on AI abuses

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

MoonLake credibility takes another hit with mid

ChatGPT in medicine: STAT answers readers' burning questions

Is mRNA technology the right fit for flu shots? Experts aren’t so sure

At least 13 dead in Texas as scorching temps continue

Flagship Pioneering launches a new biotech in two countries

knowledge

How to pay for weight loss drugs and save Medicare

Is mRNA technology the right fit for flu shots? Experts aren’t so sure

As biotech industry slumps, bioscience job market is upside down

Disappointing trial forces Pfizer to pivot on obesity medicine plans

FDA approves potent Eli Lilly obesity drug, Zepbound

Removing probiotics from the NICU could threaten preemies' health

explore

knowledge

leisure time

explore